GILEAD | Medical Information

Veklury® (remdesivir) Use of COVID-19 Vaccines

This document is in response to your request for information regarding Veklury® (remdesivir) and use of COVID-19 vaccines.

Some data may be outside of the US FDA-approved Prescribing Information. In providing this data, Gilead Sciences, Inc. is not making any representation as to its clinical relevance or to the use of any Gilead product(s). For information about the approved conditions of use of any Gilead drug product, please consult the FDA approved prescribing information.

The full indication, important safety information, and boxed warnings are available at: www.gilead.com/-/media/files/pdfs/medicines/covid-19/veklury/veklury_pi.

Product Labeling

Subjects in RDV clinical trials NIAID ACTT-1, GS-US-540-5773 (SIMPLE severe), GS-US-540-5774 (SIMPLE moderate), GS-US-540-9012 (PINETREE), and GS-US-540-5823 (CARAVAN) were unvaccinated for COVID-19.[1]

Study GS-US-540-5912 evaluated RDV 200 mg once daily for 1 day followed by RDV 100 mg once daily for 4 days (for a total of up to 5 days of intravenously administered therapy) in 243 hospitalized adult subjects with confirmed COVID-19 and renal impairment. 31 subjects (13%) had received a COVID-19 vaccine.[1] Outcomes by vaccination status have not been published.

Available Data

Currently, there are no data available on RDV and the use of COVID-19 vaccines.

Please refer to the manufacturer of the appropriate COVID-19 vaccine for additional information.

Literature Search

A literature search was conducted in Ovid MEDLINE and Embase databases for studies published between 1946 and March 14, 2025 using search terms that included Veklury, remdesivir, GS-5734, GS-441524, COVID-19 vaccine and related search terms. No relevant citations were found.

References

1. Enclosed. Gilead Sciences Inc. Veklury® (remdesivir) for injection, for intravenous use. VEKLURY® (remdesivir) injection, for intravenous use. U.S. Prescribing Information. Foster City, CA.

Abbreviations

ACTT=Adaptive COVID-19 Treatment Trial

CARAVAN=Clinical Administration of RDV After COVID-19 Diagnosis in Children

COVID-19=coronavirus disease 2019

RDV=remdesivir

Product Label

For the full indication, important safety information, and boxed warning(s), please refer to the Veklury US Prescribing Information available at: www.gilead.com/-/media/files/pdfs/medicines/covid-19/veklury/veklury_pi.

Follow Up

For any additional questions, please contact Gilead Medical Information at:

☎1-866-MEDI-GSI (1-866-633-4474) or 🖱 www.askgileadmedical.com

Adverse Event Reporting

Please report all adverse events to:

Gilead Global Patient Safety ☎ 1-800-445-3235, option 3 or
🖱 www.gilead.com/utility/contact/report-an-adverse-event

FDA MedWatch Program by ☎ 1-800-FDA-1088 or ✉MedWatch, FDA, 5600 Fishers Ln, Rockville, MD 20852 or 🖱 www.accessdata.fda.gov/scripts/medwatch

Data Privacy

The Medical Information service at Gilead Sciences may collect, store and use your personal information to provide a response to your medical request. We may share your information with other Gilead Sciences colleagues to ensure that your request is addressed appropriately. If you report an adverse event or concern about the quality of a Gilead or Kite product, we will need to use the information you have given us in order to meet our regulatory requirements in relation to the safety of our medicines.

It may be necessary for us to share your information with Gilead's affiliates, business partners, service providers and regulatory authorities located in countries besides your own. Gilead Sciences has implemented measures to protect the personal information you provide. Please see the Gilead Privacy Statement (www.gilead.com/privacy-statements) for more information about how Gilead handles your personal information and your rights. If you have any further questions about the use of your personal information, please contact privacy@gilead.com.